The Wall Street Journal reported today that GlaxoSmithKline PLC disclosed that it is responding to subpoenas issued by the U.S. Department of Justice concerning the development and marketing of its diabetes drug Avandia. In addition, the company announced that it had received several “civil investigation demands” from multiple states Attorneys General offices.
A Senate Finance Committee report earlier this year alleged that GlaxoSmithKline had for several years suppressed the disclosure of data linking Avandia to an increased risk of cardiovascular events. It is assumed that the Department of Justice subpoenas inquire into whether the company withheld these safety concerns about Avandia from federal regulators and the public.
Pope McGlamry has been aggressively pursuing their clients’ claims against GlaxoSmithKline for cardiovascular events suffered as a result of taking Avandia.
Disclaimer: All use of the Avandia mark is for informational and product identification purposes only. This post should not be taken as either medical or legal advice, but instead should act as a resource in providing general information that may be useful to the general public. Pope McGlamry is not affiliated with the drug manufacturer GlaxoSmithKline or its distributors.
